Related Experiment Video

Updated: Jul 26, 2026

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Lack of toxicity from pediatric beta-blocker exposures

J N Love1, J M Howell, W Klein-Schwartz

  • 1Department of Emergency Medicine, Georgetown University Hospital, Ground Floor CCC bldg, 3800 Reservoir Rd, NW, Washington, DC 20007, USA. jeffrey.n.love@medstar.net

Human & Experimental Toxicology
|July 27, 2006
PubMed

Insights

Unintentional beta-blocker exposure in young children poses minimal toxicity risk. Ingestion of one or two tablets rarely causes serious adverse effects, indicating a low risk profile for pediatric beta-blocker poisoning.

Area of Science:

  • Pediatric Toxicology
  • Cardiovascular Pharmacology

Background:

  • Uncertainty exists regarding the toxicity risk of beta-blocker exposure in children.
  • Accidental ingestion of beta-blocker medications is a common pediatric poisoning scenario.

Purpose of the Study:

  • To define the risk of toxicity in pediatric patients following unintentional beta-blocker exposure.
  • To specifically assess the outcomes of ingesting one or two beta-blocker tablets in children.

Main Methods:

  • A prospective cohort study involving 208 pediatric patients (6 months to 6 years).
  • Data collected via standardized instruments over a minimum 24-hour follow-up period.
  • Involvement of two regional poison centers.

Main Results:

  • No serious toxicity symptoms (e.g., shock, arrhythmias, seizures) were observed.
  • No episodes of hypoglycemia, symptomatic bradycardia, or bronchospasm were reported.
  • Nine cases of minor altered mental status or behavioral changes occurred; the most severe outcome was charcoal aspiration.

Conclusions:

  • Ingestion of one or two beta-blocker tablets by children is associated with a very low risk of toxicity.
  • Current evidence suggests limited danger from small-dose beta-blocker exposures in pediatric populations.

More Related Videos

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...